3 Reasons Bristol-Myers' $90 Billion Mega-Merger Makes It A Must Own Stock

|
About: Bristol-Myers Squibb Company (BMY), CELG
by: Dividend Sensei
This article is exclusive for subscribers.
Summary

The worst correction in a decade has left lots of blue-chips trading at attractive prices.

Bristol-Myers Squibb has been pummelled especially hard due to negative pharma sentiment plus now worries over its upcoming $90 billion Celgene acquisition.

While there are plenty of risks facing Bristol (and all drug makers), the deal makes great strategic sense and the company's track record on M&A is strong.

Today Bristol represents a Grade A pharma blue-chip that's at least 25% undervalued, creating a great long-term buying opportunity.

From today's prices, Bristol should be able to deliver about 17% to 20% long-term total returns, making it one of the best dividend growth stocks you can buy.

(Source: imgflip)

There's nothing like the worst correction in a decade to put great dividend growth stocks on sale. That's especially true when industry/company specific news combines to create a perfect storm of negativity